`BIB_348`

NHS England Clinical Commissioning Policy Proposition (April 2026) — Neoadjuvant followed by adjuvant pembrolizumab for Stage III macroscopic cutaneous melanoma.

Evidence grade: A
Tier: 1 (NHS En
Cited by tasks: 17, 18, 19a
Identifiers: —

↗ Follow the original source for full context

Full extracted findings & patient-implication analysis: bibliography/BIB_348/findings.md (research corpus). This page is a short context summary — not individualised medical advice.